Better tArgetting, Better Outcomes for Frail ELderly Patients (BABEL)

Better tArgetting, Better Outcomes for Frail ELderly Patients: A Quality Improvement Initiative in Long-term Care Facilities Using interRAI Long-term Care Assessment in Quebec

The acronym for this proposal, BABEL, refers to the fact that a common "language" - the interRAI risk-stratification and decision-making tool - will be used in this project, allowing several measures of care quality in long-term care facilities to be compared with those in other provinces for the first time. The impact of the use of this assessment system and associated care planning protocols will also be investigated using usual practice as the point of reference.

Study Overview

• Status: Completed
• Conditions: Residents in Longterm Care Facilities
• Intervention / Treatment: Other: interRAI LTCF

• Study Type: Observational
• Enrollment (Actual): 5692

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montréal, Quebec, Canada, H4W 2Y6
      • Donald Berman Maimonides

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Residents in a long-term care facility (nursing home)

Description

Inclusion Criteria:

• All nursing home residents in a particular unit where standardized evaluations are being introduced (for example, all residents in a particular floor or wing of the longterm care facility)

Exclusion Criteria:

• Residents who are admitted to a nursing home unit for less than 1 week.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
interRAI LTCF; Nursing homes in Quebec where interRAI evaluations and care plans will be introduced.	Other: interRAI LTCF; Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in depression prevalence	Depression rating scale score of 3 or more (from interRAI LTCF)	Every 3 months, for a minimum of 6 months and a maximum of 36 months
Change in prevalence of potentially inappropriate antipsychotic use	Use of antipsychotics in the absence of an appropriate diagnosis	Every 3 months, for a minimum of 6 months and a maximum of 36 months
Change in falls prevalence	Prevalence of falls among residents under study	Every 3 months, for a minimum of 6 months and a maximum of 36 months
Change in prevalence of pain	Using interRAI pain scale scores greater than 0	Every 3 months, for a minimum of 6 months and a maximum of 36 months
Change in the prevalence of physical restraints use	Use of physical restraints on residents as assessed using interRAI LTCF	Every 3 months, for a minimum of 6 months and a maximum of 36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in prevalence of pressure ulcers	Stage 2 pressure ulcer on the interRAI pressure ulcer scale	Every 3 months, for a minimum of 6 months and a maximum of 36 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in other interRAI LTCF quality indicators	interRAI LTCF evaluation leads to a number of quality indicators being generated each of which will be tracked over time for each facility to compare before and after effects, as well as comparisons with other centers in Canada	Every 3 months, for a minimum of 6 months and a maximum of 36 months

Collaborators and Investigators

• Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
• Collaborators: Canadian Frailty Network

Study record dates

Study Major Dates

• Study Start (Actual): August 16, 2018
• Primary Completion (Actual): March 31, 2020
• Study Completion (Actual): March 31, 2020

Study Registration Dates

• First Submitted: June 20, 2018
• First Submitted That Met QC Criteria: September 5, 2023
• First Posted (Actual): September 13, 2023

Study Record Updates

• Last Update Posted (Actual): September 13, 2023
• Last Update Submitted That Met QC Criteria: September 5, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 17.205

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No